STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] Meihua International Medical Technologies Co., Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Meihua International Medical Technologies Co., Ltd. (MHUA) reported the results of an extraordinary general meeting held on November 8, 2025. Shareholders holding 38,358,424 of the 55,904,468 ordinary shares outstanding were present in person or by proxy, satisfying the quorum requirement.

Shareholders approved a share consolidation that changes the Company’s authorized share capital from USD50,000 divided into 80,000,000 ordinary shares and 20,000,000 preferred shares, each with a par value of USD0.0005, to USD50,000 divided into 800,000 ordinary shares and 200,000 preferred shares, each with a par value of USD0.05. The voting results on the resolutions showed a very high level of support, with the main proposal receiving 38,304,099 votes in favor, 34,500 against and 27 abstentions.

Positive
  • None.
Negative
  • None.

Insights

MHUA shareholders approved a high-support share consolidation that restructures authorized capital without changing total nominal equity.

The company obtained strong shareholder participation, with 38,358,424 of 55,904,468 ordinary shares represented at the extraordinary general meeting. A key resolution was the share consolidation that keeps total authorized capital at USD50,000 but reduces the number of authorized ordinary shares from 80,000,000 to 800,000 and preferred shares from 20,000,000 to 200,000, while increasing par value from USD0.0005 to USD0.05 per share.

The voting outcome indicates broad support, as one resolution received 38,304,099 votes for versus 34,500 against with 27 abstentions. Because total authorized capital remains unchanged, the consolidation is primarily a re-denomination of share counts and par values rather than an economic change in aggregate nominal capital. Subsequent disclosures in future company filings may clarify any operational or listing-related motivations linked to this capital structure adjustment.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2025

 

Commission File Number 001-41291

 

MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.

(Translation of registrant’s name into English)

 

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

 

Submission of Matters to a Vote of Security Holders.

 

Meihua International Medical Technologies Co., Ltd., a Cayman Islands exempted company (the “Company”) held an extraordinary general meeting of the holders of the Company’s shares (the “Meeting”) on November 8, 2025 at 9:00 AM Eastern time at the Company’s headquarters located at 88 Tongda Road, Touqiao Town, Guangling District, Yangzhou, People’s Republic of China 225000. Holders of a total of 38,358,424 out of a total of 55,904,468 ordinary shares (the “Ordinary Shares”) issued and outstanding and entitled to vote at the Meeting, that one or more members of the Company was present in person or by proxy holding at least a majority of the paid up voting share capital of the Company, and that a quorum for the transaction of business was present at the Meeting. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

 

1.It is resolved as an ordinary resolution that, with immediate effect:

 

(a)

 

(i)every one hundred (100) issued and unissued ordinary shares of par value USD0.0005 each of the Company be consolidated into one (1) consolidated ordinary share (each a “Consolidated Ordinary Share”) of par value USD0.05 each, such Consolidated Ordinary Shares shall rank pari passu in all respects with each other and be subject to the same rights and restrictions (save as to nominal value) as contained in the existing memorandum and articles of association of the Company; and

 

(ii)every one hundred (100) issued and unissued preferred shares of par value USD0.0005 each of the Company be consolidated into one (1) consolidated preferred share (each a “Consolidated Preferred Share”) of par value USD0.05 each, such Consolidated Preferred Shares shall rank pari passu in all respects with each other and be subject to the same rights and restrictions (save as to nominal value) as contained in the existing memorandum of association and articles of association of the Company,

 

(together, the “Share Consolidation”), so that following the Share Consolidation, the authorized share capital of the Company will be changed from USD50,000 divided into (i) 80,000,000 ordinary shares of par value USD0.0005 each and (ii) 20,000,000 preferred shares of par value USD0.0005 each to USD50,000 divided into (i) 800,000 ordinary shares of par value USD0.05 each and (ii) 200,000 preferred shares of par value USD0.05 each.

 

(b)no fractional shares be issued in connection with the Share Consolidation and, in the event that a shareholder would otherwise be entitled to receive a fractional share upon the Share Consolidation, the number of Shares to be received by such shareholder be rounded up to the next highest whole number of Shares (together with 1(a), the “Share Consolidation Proposal”).

 

For     Against     Abstain  
  38,304,099       34,500       27  

 

2.It is resolved as an ordinary resolution that, immediately following the Share Consolidation, the authorized share capital of the Company be increased from USD50,000 divided into (i) 800,000 ordinary shares of par value USD0.05 each and (ii) 200,000 preferred shares of par value USD0.05 each to USD500,000,000 divided into (i) 8,000,000,000 ordinary shares of par value USD0.05 each and (ii) 2,000,000,000 preferred shares of par value USD0.05 each, by the creation of 7,999,200,000 ordinary shares of USD0.05 each and 1,999,8000,000 preferred shares of USD0.05 each (the “Increase of the Authorized Share Capital”).

  

For     Against     Abstain  
  38,076,285       260,946       1,395  

 

1

 

 

3.It is resolved as a special resolution that, immediately following the Increase of the Authorized Share Capital:

 

(a)7,000,000,000 of the authorized ordinary shares of par value USD0.05 each (including all of the existing issued ordinary shares) in the Company will be re-designated and re-classified as 7,000,000,000 class A ordinary shares of par value USD0.05 each (the “Class A Ordinary Shares”), where the rights of the existing ordinary shares shall be the same as the Class A Ordinary Shares;

 

(b)1,000,000,000 of the authorized but unissued ordinary shares of par value of USD0.05 each in the Company will be cancelled and a new class of shares comprising of 1,000,000,000 class B ordinary shares of par value USD0.05 each (the “Class B Ordinary Shares”), which shall have the rights and subject to the restrictions set forth in the second amended and restated memorandum and articles of association to be adopted by the Company pursuant to resolution 4 below, will be created; and such that the authorized share capital of the Company shall become USD500,000,000 divided into (i) 7,000,000,000 Class A Ordinary Shares of a par value of USD0.05 each; (ii) 1,000,000,000 Class B Ordinary Shares of a par value of USD0.05 each and (c) 2,000,000,000 preferred shares of a par value of USD0.05 each (the “Share Capital Amendment”), and that following the Share Capital Amendment having taken effect, and upon the Company’s receipt of the consent to repurchase and application for shares as duly executed by Bright Accomplish Limited (“BAL”), the Company shall repurchase 159,350 Class A Ordinary Shares held by BAL, all of which are fully paid shares, in consideration of and out of the proceeds of the Company’s new issuance of 159,350 Class B Ordinary Shares to BAL, and such issuance of 159,350 Class B Ordinary Shares to BAL be and is hereby approved and confirmed (collectively, the “Share Capital Amendment Proposal”).

 

For     Against     Abstain  
  38,077,397       260,946       283  

  

4. It is resolved as a special resolution that, conditional upon the Share Consolidation Proposal, the Increase of Authorized Share Capital and the Share Capital Amendment Proposal having been duly approved by the shareholders of the Company, the amended and restated memorandum and articles of association of the Company adopted by special resolutions dated December 21, 2020, be amended and restated by the deletion in their entirety and by the substitution in their place of the second amended and restated memorandum and articles of association in the form as attached hereto as Appendix A (the “Amended M&AA”) to reflect, inter alia, the proposed resolutions set forth herein.

 

For     Against     Abstain  
  38,075,653       218,169       44,804  

 

5. It is resolved as an ordinary resolution, to approve and adopt the Company’s 2025 Equity Incentive Plan (the “2025 Plan”) and all transactions contemplated thereunder, including the reservation and issuance of shares.

 

For     Against     Abstain  
  38,075,653       218,169       44,804  

 

6. It is resolved as an ordinary resolution that any one or more of the directors of the Company be and is hereby authorized to do all such acts and things and execute all such documents and deliver all such documents, which are ancillary to the Share Consolidation Proposal, the Increase of the Authorized Share Capital, the Share Capital Amendment Proposal, the adoption of the Amended M&AA, and the adoption of the 2025 Plan, including but not limited to, making any relevant registrations and filings with any authorities in accordance with the applicable laws, rules and regulations, as any of them considers necessary, desirable or expedient to give effect to the foregoing arrangements for the Share Consolidation, the Increase of the Authorized Share Capital, the Share Capital Amendment Proposal, the adoption of the Amended M&AA, and the adoption of the 2025 Plan; the registered office provider of the Company be instructed to make all necessary filings with the Registrar of Companies of the Cayman Islands in connection with the Share Consolidation, the Increase of the Authorized Share Capital, the Share Capital Amendment Proposal, the adoption of the Amended M&AA, and the adoption of the 2025 Plan; and the Company’s share registrar be instructed to update the register of members of the Company and that upon the surrender to the Company of the existing share certificates (if any) that they be cancelled and that any director of the Company be instructed to prepare, sign, seal and deliver on behalf of the Company new share certificates accordingly.

 

For     Against     Abstain  
  38,075,653       218,169       44,804  

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: November 18, 2025

 

  MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.
     
  By: /s/ Leyi Lee
  Name:  Leyi Lee
  Title: Chief Executive Officer

 

 

3

 

 

FAQ

What did Meihua International Medical Technologies (MHUA) shareholders vote on?

Shareholders voted at an extraordinary general meeting to approve a share consolidation that restructures the Company’s authorized ordinary and preferred share capital while keeping total authorized capital at USD50,000.

How many MHUA shares were represented at the November 2025 extraordinary meeting?

Holders of 38,358,424 ordinary shares out of a total of 55,904,468 ordinary shares issued and outstanding were present in person or by proxy, satisfying the majority quorum requirement.

What is the new authorized share structure for MHUA after the share consolidation?

After the consolidation, authorized capital of USD50,000 is divided into 800,000 ordinary shares and 200,000 preferred shares, each with a par value of USD0.05.

What was MHUA’s authorized share structure before the consolidation?

Before the change, authorized capital of USD50,000 was divided into 80,000,000 ordinary shares and 20,000,000 preferred shares, each with a par value of USD0.0005.

How strong was shareholder support for the MHUA share consolidation resolution?

One of the main resolutions related to the share consolidation received 38,304,099 votes for, 34,500 votes against, and 27 abstentions, indicating very high support.

Does the MHUA share consolidation change total authorized capital in dollar terms?

No. The total authorized capital remains at USD50,000; the change is in the number of shares and their par value, not the aggregate nominal amount.

Meihua International Medical Technologies Co., Ltd.

NASDAQ:MHUA

MHUA Rankings

MHUA Latest News

MHUA Latest SEC Filings

MHUA Stock Data

12.71M
39.97M
49.95%
0.52%
0.05%
Medical Instruments & Supplies
Healthcare
Link
China
Yangzhou